42.49
price down icon1.58%   -0.68
after-market 시간 외 거래: 42.49
loading
전일 마감가:
$43.17
열려 있는:
$43.04
하루 거래량:
134.33K
Relative Volume:
0.31
시가총액:
$2.28B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+17.54%
1개월 성능:
+4.84%
6개월 성능:
+318.62%
1년 성능:
+322.79%
1일 변동 폭
Value
$41.67
$43.17
1주일 범위
Value
$36.16
$44.60
52주 변동 폭
Value
$5.83
$44.60

Zenas Biopharma Inc Stock (ZBIO) Company Profile

Name
명칭
Zenas Biopharma Inc
Name
전화
857-271-2954
Name
주소
852 WINTER STREET, SUITE 250, WALTHAM
Name
직원
130
Name
트위터
Name
다음 수익 날짜
Name
최신 SEC 제출 서류
Name
ZBIO's Discussions on Twitter

ZBIO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
ZBIO
Zenas Biopharma Inc
42.49 2.32B 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
462.90 117.47B 11.74B 3.68B 3.34B 14.19
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
784.97 82.37B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
400.59 52.94B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
ARGX
Argen X Se Adr
844.92 52.33B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
177.88 37.84B 447.02M -1.18B -906.14M -6.1812

Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-03-20 개시 Wedbush Outperform
2025-02-04 개시 Wolfe Research Outperform
2024-12-16 개시 H.C. Wainwright Buy
2024-11-05 개시 Rodman & Renshaw Buy
2024-10-08 개시 Citigroup Buy
2024-10-08 개시 Guggenheim Buy
2024-10-08 개시 Jefferies Buy
2024-10-08 개시 Morgan Stanley Overweight
모두보기

Zenas Biopharma Inc 주식(ZBIO)의 최신 뉴스

pulisher
Dec 26, 2025

Zenas BioPharma : Corporate Presentation - marketscreener.com

Dec 26, 2025
pulisher
Dec 25, 2025

Is Zenas BioPharma Inc. stock attractive after correctionFibonacci Extensions & Target Triple-Digit Stock Opportunities - Bollywood Helpline

Dec 25, 2025
pulisher
Dec 24, 2025

Analysts' Revenue Estimates For Zenas BioPharma, Inc. (NASDAQ:ZBIO) Are Surging Higher - simplywall.st

Dec 24, 2025
pulisher
Dec 23, 2025

Zenas BioPharma (NASDAQ:ZBIO) Hits New 52-Week HighWhat's Next? - MarketBeat

Dec 23, 2025
pulisher
Dec 22, 2025

Zenas BioPharma (NASDAQ:ZBIO) Trading 8.9% HigherShould You Buy? - MarketBeat

Dec 22, 2025
pulisher
Dec 22, 2025

Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next - ts2.tech

Dec 22, 2025
pulisher
Dec 22, 2025

Zenas Biopharma stock reaches all-time high of 41.67 USD - Investing.com

Dec 22, 2025
pulisher
Dec 22, 2025

Zenas BioPharma Seen Attractive Ahead of IgG4-RD Phase 3 Update, Wedbush Says - marketscreener.com

Dec 22, 2025
pulisher
Dec 22, 2025

Wedbush Reiterates Outperform Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat

Dec 22, 2025
pulisher
Dec 21, 2025

Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to NASDAQ Biotechnology Index - marketscreener.com

Dec 21, 2025
pulisher
Dec 21, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation - ACCESS Newswire

Dec 21, 2025
pulisher
Dec 21, 2025

2025-12-21 | Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Shareholders to Inquire about Securities Investigation | NDAQ:ZBIO | Press Release - Stockhouse

Dec 21, 2025
pulisher
Dec 20, 2025

How interest rate cuts could boost Zenas BioPharma Inc. stockRecession Risk & Weekly Hot Stock Watchlists - ulpravda.ru

Dec 20, 2025
pulisher
Dec 20, 2025

Zenas BioPharma approves 2026 inducement plan - MSN

Dec 20, 2025
pulisher
Dec 20, 2025

Can Zenas BioPharma Inc. stock reach $100 price target2025 Risk Factors & Short-Term High Return Ideas - Улправда

Dec 20, 2025
pulisher
Dec 20, 2025

Why Zenas BioPharma Inc. stock remains on buy listsJuly 2025 Technicals & Stepwise Swing Trade Plans - Улправда

Dec 20, 2025
pulisher
Dec 20, 2025

Winners Losers: What sentiment indicators say about Zenas BioPharma Inc. stock2025 Big Picture & Daily Entry Point Trade Alerts - Улправда

Dec 20, 2025
pulisher
Dec 19, 2025

Growth Value: How interest rate cuts could boost Zenas BioPharma Inc. stockShare Buyback & Weekly High Return Stock Forecasts - Улправда

Dec 19, 2025
pulisher
Dec 19, 2025

Zenas Biopharma announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Dec 19, 2025
pulisher
Dec 19, 2025

Insider Trends: How interest rate cuts could boost Zenas BioPharma Inc. stock - Улправда

Dec 19, 2025
pulisher
Dec 19, 2025

Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets

Dec 19, 2025
pulisher
Dec 19, 2025

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Dec 19, 2025
pulisher
Dec 19, 2025

Is Zenas BioPharma Inc. stock resilient to inflationJuly 2025 Retail & Step-by-Step Trade Execution Guides - DonanımHaber

Dec 19, 2025
pulisher
Dec 19, 2025

What insider trading reveals about Zenas BioPharma Inc. stockJuly 2025 Chart Watch & Low Risk Entry Point Guides - DonanımHaber

Dec 19, 2025
pulisher
Dec 18, 2025

New Highs: How interest rate cuts could boost Zenas BioPharma Inc. stockTrade Risk Summary & Risk Controlled Stock Alerts - Улправда

Dec 18, 2025
pulisher
Dec 18, 2025

Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Connect - ACCESS Newswire

Dec 18, 2025
pulisher
Dec 18, 2025

Earnings Report: Is Zenas BioPharma Inc stock a bargain at current levelsJuly 2025 Earnings & Free Community Supported Trade Ideas - moha.gov.vn

Dec 18, 2025
pulisher
Dec 17, 2025

Orelabrutinib’s SLE Phase 2b Success Could Be A Game Changer For Zenas BioPharma (ZBIO) - Sahm

Dec 17, 2025
pulisher
Dec 16, 2025

H.C. Wainwright reiterates Buy rating on Zenas Biopharma stock amid competitor setback - Investing.com Canada

Dec 16, 2025
pulisher
Dec 16, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zenas BioPharma, Inc. (ZBIO) And Encourages Shareholders to Reach Out - ACCESS Newswire

Dec 16, 2025
pulisher
Dec 16, 2025

Zenas BioPharma (NASDAQ:ZBIO) Trading 6.7% HigherTime to Buy? - MarketBeat

Dec 16, 2025
pulisher
Dec 16, 2025

Zenas BioPharma Shares Surge Amid Promising Drug Trials - TipRanks

Dec 16, 2025
pulisher
Dec 16, 2025

Buy Rating Reaffirmed for Zenas BioPharma: Promising Orelabrutinib Developments and Autoimmune Platform Potential - TipRanks

Dec 16, 2025
pulisher
Dec 16, 2025

Promising Developments in Zenas BioPharma’s Orelabrutinib Drive Buy Rating Amidst Competitive Advantage and Expected Share Price Upside - TipRanks

Dec 16, 2025
pulisher
Dec 16, 2025

Zenas BioPharma and InnoCare hit key milestone in Lupus drug trial, secures China Phase 3 nod - Indian Pharma Post

Dec 16, 2025
pulisher
Dec 16, 2025

Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Dec 16, 2025
pulisher
Dec 16, 2025

Zenas BioPharma (ZBIO): Reassessing Valuation After Orelabrutinib’s Phase 2b Lupus Success and China Phase 3 Green Light - Yahoo Finance

Dec 16, 2025
pulisher
Dec 15, 2025

Zenas BioPharma (ZBIO): Reassessing a Rich Valuation After Positive Orelabrutinib Lupus Trial Milestones - Sahm

Dec 15, 2025
pulisher
Dec 15, 2025

Zenas BioPharma Approves 2026 Inducement Plan - TipRanks

Dec 15, 2025
pulisher
Dec 15, 2025

Zenas BioPharma (NASDAQ:ZBIO) Shares Down 9.9%Should You Sell? - MarketBeat

Dec 15, 2025
pulisher
Dec 15, 2025

ZBIO STOCKHOLDERS: Contact Robbins LLP for Information About How - GuruFocus

Dec 15, 2025
pulisher
Dec 15, 2025

InnoCare Pharma achieves primary endpoint in Phase 2b study of orelabrutinib - TipRanks

Dec 15, 2025
pulisher
Dec 15, 2025

Innocare Pharma announces achievement of primary endpoint in phase 2b study of orelabrutinib - marketscreener.com

Dec 15, 2025
pulisher
Dec 15, 2025

Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus - The Manila Times

Dec 15, 2025
pulisher
Dec 15, 2025

Zenas Prepares For INDIGO Phase 3 Readout—Reinstating Buy Rating (ZBIO) - Seeking Alpha

Dec 15, 2025
pulisher
Dec 15, 2025

Zenas BioPharma Says Partner InnoCare's Phase 2b Orelabrutinib Study in Systemic Lupus Erythematosus Meets Primary Endpoint - marketscreener.com

Dec 15, 2025
pulisher
Dec 14, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire

Dec 14, 2025
pulisher
Dec 12, 2025

IgG4-related Disease Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Zenas BioPharma, Horizon Therapeutics, Amgen, Sanofi, UMC Utrecht - The Globe and Mail

Dec 12, 2025
pulisher
Dec 11, 2025

Is Zenas BioPharma’s (ZBIO) Royalty Deal Quietly Rewriting Its Late-Stage Risk Profile? - Sahm

Dec 11, 2025
pulisher
Dec 11, 2025

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire

Dec 11, 2025
pulisher
Dec 11, 2025

Federated Hermes Inc. Boosts Stake in Zenas BioPharma, Inc. $ZBIO - MarketBeat

Dec 11, 2025

Zenas Biopharma Inc (ZBIO) 재무 분석

Zenas Biopharma Inc (ZBIO)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$39.22
price down icon 0.08%
$100.11
price down icon 0.33%
$33.42
price down icon 0.89%
$94.52
price down icon 0.54%
biotechnology ONC
$312.39
price up icon 0.21%
$177.88
price up icon 0.26%
자본화:     |  볼륨(24시간):